Troxacitabine

DB04961InvestigationalSmall molecule

Troxacitabine is a nucleoside analog with antineoplastic activity. There has been growing interest in its development for the treatment of patients with refractory lymphoproliferative conditions.

Mechanism: Troxacitabine is activated by cellular kinases and incorporated into DNA, inhibiting its replication. In contrast to other cytosine nucleoside analogs, troxacitabine is resistant to inactivation by cytidine deaminase (CD).
Curator reviewed
Primary indication: Investigated for use/treatment in leukemia (myeloid).Curator reviewed
Formula / weight: C₈H₁₁N₃O₄ · 213.1906 g/mol (avg)
Code names: BCH-4556

Resolves to

Compound

UNII60KQZ0388YCAS145918-75-8ChEMBLCHEMBL359164ChEBI134886PubChem454194

Structure

InChIKeyRXRGZNYSEHTMHC-BQBZGAKWSA-NSMILESNC1=NC(=O)N(C=C1)[C@@H]1CO[C@H](CO)O1

What you can answer from here — as of January 14, 2023

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

39Drug interactionsStructured to mechanism, not free text

4Clinical trialsPhase, status and sponsor resolved per trial

9+ReferencesStructured and connected to the statements they support

Which companies are running trials of Troxacitabine, in which indications and phases, and which of those programs are still active?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account